TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: GlobeNewswire
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company’s anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). BRIUMVI is currently approved in the United States, as well as several ex-US territories, as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in adults with RMS. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “We are very pleased to announce the commencement of patient enrollment in our Phase 3 trial of subcutaneous BRIUMVI. This marks an important milestone for TG in our subcutaneous development program. If successful, BRIUMVI would be the only anti-CD20 therapy to offer an IV healthcare provider administered option, as well as an at home subcutaneous self-administered option, providing greater flexibility a
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- TG Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing CompaniesGlobeNewswire
- TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing [Seeking Alpha]Seeking Alpha
TGTX
Earnings
- 11/3/25 - Beat
TGTX
Sec Filings
- 11/25/25 - Form 4
- 11/24/25 - Form 144
- 11/10/25 - Form SCHEDULE
- TGTX's page on the SEC website